

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI207864

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	SECURITY INTEREST	
CONVEYING PARTY DATA		
Name		Execution Date
ANDE Corporation		05/01/2024
RECEIVING PARTY DATA		
Company Name:	OrbiMed Royalty & Credit Opportunities IV, LP	
Street Address:	601 Lexington Avenue	
Internal Address:	54th Floor	
City:	New York	
State/Country:	NEW YORK	
Postal Code:	10022	
PROPERTY NUMBERS Total: 24		
Property Type	Number	
Patent Number:	9797841	
Patent Number:	9889449	
Patent Number:	9994895	
Patent Number:	10464065	
Patent Number:	10538804	
Patent Number:	10821445	
Patent Number:	11022555	
Patent Number:	11052398	
Patent Number:	11110461	
Patent Number:	11168318	
Patent Number:	11441173	
Patent Number:	11612893	
Patent Number:	11612894	
Patent Number:	11900604	
Application Number:	16257780	
Application Number:	16411908	
Application Number:	17492318	
Application Number:	17258434	
Application Number:	17836825	

Property Type	Number
Application Number:	17818194
Application Number:	18172189
Application Number:	16594857
Application Number:	18234946
Application Number:	18391117

CORRESPONDENCE DATA

Fax Number:
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 8004945225
Email: ipteam@cogencyglobal.com
Correspondent Name: Stewart Walsh
Address Line 1: 1025 Connecticut Ave NW, Suite 712
Address Line 2: Cogency Global Inc.
Address Line 4: Washington, DISTRICT OF COLUMBIA 20036

ATTORNEY DOCKET NUMBER:	2360766 PAT
NAME OF SUBMITTER:	Andrew Hackett
SIGNATURE:	Andrew Hackett
DATE SIGNED:	05/02/2024

Total Attachments: 7
source=OrbiMed - ANDE - Patent Security Agreement#page1.tif
source=OrbiMed - ANDE - Patent Security Agreement#page2.tif
source=OrbiMed - ANDE - Patent Security Agreement#page3.tif
source=OrbiMed - ANDE - Patent Security Agreement#page4.tif
source=OrbiMed - ANDE - Patent Security Agreement#page5.tif
source=OrbiMed - ANDE - Patent Security Agreement#page6.tif
source=OrbiMed - ANDE - Patent Security Agreement#page7.tif

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT, dated as of May 1, 2024 (this “**Patent Security Agreement**”), made by each of the signatories hereto (together with any other entity that may become a party hereto as provided herein, the “**Patent Grantors**”), is in favor of OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent for the Secured Parties (in such capacity, together with its successors and assigns, the “**Agent**”).

W I T N E S S E T H:

WHEREAS, the Patent Grantors are party to a Security Agreement dated as of April May 1, 2024 (as amended or otherwise modified from time to time, the “**Security Agreement**”) in favor of the Agent, pursuant to which the Patent Grantors are required to execute and deliver this Patent Security Agreement (capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Security Agreement);

WHEREAS, pursuant to the terms of the Security Agreement, each Patent Grantor has created in favor of the Agent a security interest in, and the Agent has become a secured creditor with respect to, the Patent Collateral (as defined below);

NOW, THEREFORE, in consideration of the premises and to induce the Agent and the Lender to enter into the Credit Agreement and to induce the Lender to make their respective extensions of credit to the Borrower thereunder, each Patent Grantor hereby grants to the Agent, for the ratable benefit of the Secured Parties, a security interest in all of the following property now owned or at any time hereafter acquired by such Patent Grantor or in which such Patent Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the “**Patent Collateral**”), as collateral security for the complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of all Secured Obligations:

(a) all Patents of such Patent Grantor, including, without limitation, the registered and applied-for Patents of such Grantor listed on **Schedule 1** attached hereto;

(b) to the extent not covered by **clause (a)**, all Proceeds of any of the foregoing;
and

(c) to the extent not covered by **clause (a)**, all causes of action arising prior to or after the date hereof for infringement of any of the Patents.

The security interest granted pursuant to this Patent Security Agreement is granted in conjunction with the security interest granted to the Agent pursuant to the Security Agreement, and the Patent Grantors hereby acknowledge and affirm that the rights and remedies of the Agent with respect to the security interest in the Patents made and granted hereby are more fully set forth in the Security Agreement. In the event that any provision of this Patent Security Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

Each Patent Grantor hereby authorizes and requests that the Commissioner of Patents and Trademarks record this Patent Security Agreement.

THIS PATENT SECURITY AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS PATENT SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.

This Patent Security Agreement may be executed by one or more of the parties to this Patent Security Agreement on any number of separate counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of an executed signature page of this Patent Security Agreement by facsimile transmission or electronic transmission (in PDF format) shall be effective as delivery of a manually executed counterpart hereof.

[Signature Pages Follow]

IN WITNESS WHEREOF, each Patent Grantor has caused this Patent Security Agreement to be executed and delivered by its duly authorized officer as of the date first above written.

ANDE CORPORATION

By: 

Name: George Heinrichs

Title: Chief Executive Officer


Address: 1860 Industrial Cir, Ste A,
Longmont, CO 80501

Accepted and Agreed:

ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, as administrative agent

By OrbiMed ROF IV LLC, its general partner

By: OrbiMed Advisors LLC, its Managing Partner

By: 
Name: Matthew Rizzo
Title: Member

Address for Notices:

OrbiMed Royalty & Credit Opportunities IV, LP
c/o OrbiMed Advisors LLC
601 Lexington Avenue 54th Floor
New York, NY 10022
Attention: Matthew Rizzo; OrbiMed Credit Reporting
Email: RizzoM@OrbiMed.com; RoSCreditOps@OrbiMed.com

With a copy (which shall not constitute notice) to:

Morrison & Foerster LLP
250 West 55th Street
New York, NY 10019
Attn: Mark S. Wojciechowski
Tel.: (212) 468 - 8079
Email: MWojciechowski@mofo.com

PATENTSPatent Registrations and Applications

Patent	Patent No.	Reg. No. (App. No.)	Reg. Date (App. Date)	Owner
Methods and compositions for rapid multiplex amplification of STR loci	9797841	13/804881	03/14/2013	ANDE Corporation
Integrated systems for the multiplexed amplification and detection of six and greater dye labeled fragments	9889449	15/151147	05/10/2016	ANDE Corporation
Plastic microfluidic separation and detection platforms	9994895	14/595785	01/13/2015	ANDE Corporation
Nucleic acid purification	10464065	15/284023	10/03/2016	ANDE Corporation
Methods for forensic DNA quantitation	10538804	15/410399	01/19/2017	ANDE Corporation
Unitary biochip providing sample-in to results out processing and methods of manufacture	10821445	15/144245	05/02/2016	ANDE Corporation
Methods and compositions for rapid multiplex application of STR loci	11022555	15/784929	10/16/2017	ANDE Corporation
Plastic microfluidic separation and detection platforms	11052398	16/002079	06/07/2018	ANDE Corporation
Integrated nucleic acid analysis	11110461	15/894630	02/12/2018	ANDE Corporation
Systems and methods for rapid nucleic acid extraction, purification and analysis from bone and tooth	11168318	15/898156	02/15/2018	ANDE Corporation

Patent	Patent No.	Reg. No. (App. No.)	Reg. Date (App. Date)	Owner
Optical instruments and systems for forensic DNA quantitation	11441173	16/729224	02/15/2018	ANDE Corporation
Unitary biochip providing sample-in to results out processing and methods of manufacture	11612893	15/368180	12/02/2016	ANDE Corporation
Unitary biochip providing sample-in to results out processing and methods of manufacture	11612894	15/416603	01/26/2017	ANDE Corporation
Adaptive expert system for analysis and classification of DNA sample data	11900604	16/034058	07/12/2018	ANDE Corporation
RUGGEDIZED APPARATUS FOR ANALYSIS OF NUCLEIC ACID AND PROTEINS	N/A	16/257780	01/25/2019	ANDE Corporation
METHODS FOR RAPID MULTIPLEXED AMPLIFICATION OF TARGET NUCLEIC ACIDS	N/A	16/411908	05/14/2019	ANDE Corporation
Systems and Methods for Rapid Nucleic Acid Extraction, Purification and Analysis from Semen	N/A	17/492318	10/01/2021	ANDE Corporation
Multiplexed Fuel Analysis	N/A	17/258434	07/29/2019	ANDE Corporation
Optical Instruments and Systems for Forensic DNA Quantitation	N/A	17/836825	06/09/2022	ANDE Corporation
Optical Instruments and Systems for Forensic DNA Quantitation	N/A	17/818194	08/08/2022	ANDE Corporation
Unitary Biochip Providing Sample-in to Results-Out Processing and Methods of Manufacture	N/A	18/172189	02/21/2023	ANDE Corporation
NUCLEIC ACID PURIFICATION	N/A	16/594857	10/07/2019	ANDE Corporation

Patent	Patent No.	Reg. No. (App. No.)	Reg. Date (App. Date)	Owner
ADAPTIVE EXPERT SYSTEM FOR ANALYSIS AND CLASSIFICATION OF DNA DATA	N/A	18/234946	08/17/2023	ANDE Corporation
Multiplex Fuel Analysis	N/A	18/391,117	02/06/2024	ANDE Corporation